Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBITDA: 2010-2024

Historic EBITDA for Whitehawk Therapeutics (WHWK) over the last 13 years, with Dec 2024 value amounting to -$63.7 million.

  • Whitehawk Therapeutics' EBITDA fell 41.15% to -$17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.5 million, marking a year-over-year increase of 74.82%. This contributed to the annual value of -$63.7 million for FY2024, which is 2.93% up from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' EBITDA is -$63.7 million, which was up 2.93% from -$65.6 million recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' EBITDA registered a high of -$4.5 million during FY2020, and its lowest value of -$110.7 million during FY2021.
  • In the last 3 years, Whitehawk Therapeutics' EBITDA had a median value of -$63.7 million in 2024 and averaged -$63.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 81.73% in 2020, then crashed by 2,380.11% in 2021.
  • Whitehawk Therapeutics' EBITDA (Yearly) stood at -$4.5 million in 2020, then slumped by 2,380.11% to -$110.7 million in 2021, then surged by 45.25% to -$60.6 million in 2022, then fell by 8.24% to -$65.6 million in 2023, then grew by 2.93% to -$63.7 million in 2024.